The collaboration will utilize EVERSANA’s integrated suite of outsourced services to commercialize and distribute Evoke Pharma Inc.’s Gimoti in the United States.
Brain-disease focused Cerevance and Takeda Pharmaceutical forged a research collaboration to tackle gastrointestinal disorders that have their roots in the central nervous system.
Leeds, UK-based 4D Pharma and Merck/MSD are developing Live Biotherapeutics vaccines, a new class of medicines.
Zelnorm was relaunched by Alfasigma USA for the treatment of irritable bowel syndrome with constipation (IBS-C).
Ardelyx’s Phase III AMPLIFY study of tenapanor achieved the clinical trial’s primary endpoint, as well as all key secondary endpoints, in treating patients with chronic kidney disease (CKD).
Ironwood Pharmaceuticals Inc. and Allergan plc announced positive topline data from a Phase IIIb clinical trial evaluating Linzess 290 mcg on multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation (IBS-C).
Innovative Health Solutions Inc. announced FDA clearance for the new device IB-Stim to treat functional abdominal pain associated with irritable bowel syndrome (IBS) in patients ages 11-18 years old.
Bausch Health Companies Inc. was selected as the successful bidder to acquire certain assets of Synergy Pharmaceuticals Inc. for a cash purchase price of approximately $195 million and the assumption of certain assumed liabilities, pursuant to the terms of the stalking horse asset purchase agreement previously entered into.
For the 11th year, Med Ad News selected new Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.
Synergy Pharmaceuticals Inc. announced that the U.S. FDA approved Trulance (plecanatide) 3-mg tablet for the once-daily treatment of irritable bowel syndrome with constipation in adults.